Skip to content

Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00645775
Enrollment
102
Registered
2008-03-28
Start date
2006-11-30
Completion date
2007-04-30
Last updated
2008-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Metabolic Syndrome, Obesity

Keywords

Weight loss, Antiobesity, Metabolic syndrome, Leptin

Brief summary

The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

Detailed description

To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants. The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis. Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.

Interventions

DIETARY_SUPPLEMENTIGOB131

Comparison of 250 mg per day of Irvingia gabonensis to placebo

Sponsors

University of Yaounde
CollaboratorOTHER
Gateway Health Alliance
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI\>26

Exclusion criteria

* Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers

Design outcomes

Primary

MeasureTime frame
Weight change10 weeks

Secondary

MeasureTime frame
Change in blood lipids and hormone levels10 weeks

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026